ARO-RAGE

DRUG2 trials

Sponsors

Arrowhead Pharmaceuticals

Conditions

Asthma

Phase 1

Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease

CompletedNCT05276570

Arrowhead PharmaceuticalsAsthma

Start: 2022-06-29End: 2025-04-16Updated: 2026-04-09

Phase 2

Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

RecruitingNCT07241546

Arrowhead PharmaceuticalsAsthma

Start: 2026-03-30End: 2028-04-01Target: 36Updated: 2026-06-23

Related Papers

Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial

Nature Medicine2026-09-09

Late Breaking Abstract - A first-in-human study of ARO-RAGE, an RNAi therapy designed to silence pulmonary RAGE expression

2023-09-094 citations